Zeitschriftenartikel zum Thema „Virus diseases – Chemotherapy“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Virus diseases – Chemotherapy" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Talib Al-Nafakh, Rana. „Epstein–Barr Virus and Rheumatoid Arthritis in Cancer Patients Undergoing Chemotherapy in Al-Najaf Province, Iraq“. Journal of Communicable Diseases 55, Nr. 04 (13.03.2024): 119–25. http://dx.doi.org/10.24321/0019.5138.202364.
Der volle Inhalt der QuelleRollinson, E. A. „Prospects for Antiviral Chemotherapy in Veterinary Medicine: 1. Feline Virus Diseases“. Antiviral Chemistry and Chemotherapy 3, Nr. 5 (Oktober 1992): 249–62. http://dx.doi.org/10.1177/095632029200300501.
Der volle Inhalt der QuelleSnoeck, R., G. Andrei und E. De Clercq. „Chemotherapy of varicella zoster virus infections“. International Journal of Antimicrobial Agents 4, Nr. 3 (August 1994): 211–26. http://dx.doi.org/10.1016/0924-8579(94)90011-6.
Der volle Inhalt der QuellePolsky, Bruce. „Antiviral Chemotherapy for Infection with Human Immunodeficiency Virus“. Clinical Infectious Diseases 11, Supplement_7 (01.11.1989): S1648—S1663. http://dx.doi.org/10.1093/clinids/11.supplement_7.s1648.
Der volle Inhalt der QuelleRice, W. G., und J. A. Turpin. „Virus-encoded Zinc Fingers as Targets for Antiviral Chemotherapy“. Reviews in Medical Virology 6, Nr. 4 (Dezember 1996): 187–99. http://dx.doi.org/10.1002/(sici)1099-1654(199612)6:4<187::aid-rmv176>3.0.co;2-f.
Der volle Inhalt der QuelleFIELD, HUGH J. „The impact of drug resistance upon virus chemotherapy“. Journal of Antimicrobial Chemotherapy 24, Nr. 1 (1989): 4–7. http://dx.doi.org/10.1093/jac/24.1.4.
Der volle Inhalt der QuelleHan, Seung Beom, Hye Jo Shin, Eui Soo Lee, Jae Wook Lee, Nack-Gyun Chung, Bin Cho und Jin Han Kang. „SEROLOGICAL CHANGES AGAINST HEPATITIS B SURFACE ANTIGEN IN CHILDREN AND ADOLESCENTS RECEIVING CHEMOTHERAPY FOR ACUTE LEUKEMIA“. Mediterranean Journal of Hematology and Infectious Diseases 11, Nr. 1 (29.08.2019): e2019052. http://dx.doi.org/10.4084/mjhid.2019.052.
Der volle Inhalt der QuelleWainberg, Mark A., Andre Dascal und Jack Mendelson. „Anti-Retroviral Strategies for AIDS and Related Diseases“. Canadian Journal of Infectious Diseases 2, Nr. 3 (1991): 121–28. http://dx.doi.org/10.1155/1991/487657.
Der volle Inhalt der QuelleBenke, Ashwini Prashant, Ram Krishna, Kiran Khandagale, Suresh Gawande, Poonam Shelke, Somnath Dukare, Sweta Dhumal, Major Singh und Vijay Mahajan. „Efficient Elimination of Viruses from Garlic Using a Combination of Shoot Meristem Culture, Thermotherapy, and Chemical Treatment“. Pathogens 12, Nr. 1 (12.01.2023): 129. http://dx.doi.org/10.3390/pathogens12010129.
Der volle Inhalt der QuelleDorobantu, Cristina M., Christian Harak, Rahel Klein, Lonneke van der Linden, Jeroen R. P. M. Strating, Hilde M. van der Schaar, Volker Lohmann und Frank J. M. van Kuppeveld. „Tyrphostin AG1478 Inhibits Encephalomyocarditis Virus and Hepatitis C Virus by Targeting Phosphatidylinositol 4-Kinase IIIα“. Antimicrobial Agents and Chemotherapy 60, Nr. 10 (01.08.2016): 6402–6. http://dx.doi.org/10.1128/aac.01331-16.
Der volle Inhalt der QuellePatel, R., und S. E. Barton. „Antiviral Chemotherapy in Genital Herpes Simplex Virus Infections“. International Journal of STD & AIDS 6, Nr. 5 (September 1995): 320–28. http://dx.doi.org/10.1177/095646249500600503.
Der volle Inhalt der QuelleRoy, Biswajit G. „Potential of small-molecule fungal metabolites in antiviral chemotherapy“. Antiviral Chemistry and Chemotherapy 25, Nr. 2 (23.07.2017): 20–52. http://dx.doi.org/10.1177/2040206617705500.
Der volle Inhalt der QuelleDe Clercq, Erik. „Acyclic Nucleoside Phosphonates in the Chemotherapy of DNA Virus and Retrovirus Infections“. Intervirology 40, Nr. 5-6 (1997): 295–303. http://dx.doi.org/10.1159/000150563.
Der volle Inhalt der QuelleYeo, Winnie, Joyce L. Steinberg, John S. Tam, Paul K. S. Chan, Nancy W. Y. Leung, Kwok C. Lam, Tony S. K. Mok und Philip J. Johnson. „Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy“. Journal of Medical Virology 59, Nr. 3 (November 1999): 263–69. http://dx.doi.org/10.1002/(sici)1096-9071(199911)59:3<263::aid-jmv1>3.0.co;2-x.
Der volle Inhalt der QuelleRollinson, E. A. „Prospects for Antiviral Chemotherapy in Veterinary Medicine: 2. Avian, Piscine, Canine, Porcine, Bovine and Equine Virus Diseases“. Antiviral Chemistry and Chemotherapy 3, Nr. 6 (Dezember 1992): 311–26. http://dx.doi.org/10.1177/095632029200300601.
Der volle Inhalt der QuelleHirsch, M. S. „Chemotherapy of Human Immunodeficiency Virus Infections: Current Practice and Future Prospects“. Journal of Infectious Diseases 161, Nr. 5 (01.05.1990): 845–57. http://dx.doi.org/10.1093/infdis/161.5.845.
Der volle Inhalt der QuelleDylewski, J., und L. Thibert. „Failure of Tuberculosis Chemotherapy in a Human Immunodeficiency Virus-Infected Patient“. Journal of Infectious Diseases 162, Nr. 3 (01.09.1990): 778–79. http://dx.doi.org/10.1093/infdis/162.3.778.
Der volle Inhalt der QuelleHenrich, Timothy J., Kristen S. Hobbs, Emily Hanhauser, Eileen Scully, Louise E. Hogan, Yvonne P. Robles, Kaitlyn S. Leadabrand et al. „Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy“. Journal of Infectious Diseases 216, Nr. 2 (03.06.2017): 254–62. http://dx.doi.org/10.1093/infdis/jix265.
Der volle Inhalt der QuelleThackray, Alana M., und Hugh J. Field. „Persistence of Infectious Herpes Simplex Virus Type 2 in the Nervous System in Mice after Antiviral Chemotherapy“. Antimicrobial Agents and Chemotherapy 44, Nr. 1 (01.01.2000): 97–102. http://dx.doi.org/10.1128/aac.44.1.97-102.2000.
Der volle Inhalt der QuelleIdilman, R., M. Arat, E. Soydan, M. Toruner, I. Soykan, H. Akbulut, O. Arslan et al. „Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies“. Journal of Viral Hepatitis 11, Nr. 2 (März 2004): 141–47. http://dx.doi.org/10.1046/j.1365-2893.2003.00479.x.
Der volle Inhalt der QuelleTien Phat, Do, Pham Bich Ngoc und Chu Hoang Ha. „Methods to manage, protect and improve plant virus resistance“. Vietnam Journal of Biotechnology 19, Nr. 4 (03.05.2022): 607–18. http://dx.doi.org/10.15625/1811-4989/15584.
Der volle Inhalt der QuelleOketani, Makoto, Akio Ido, Hirofumi Uto und Hirohito Tsubouchi. „Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy“. Hepatology Research 42, Nr. 7 (12.06.2012): 627–36. http://dx.doi.org/10.1111/j.1872-034x.2012.00998.x.
Der volle Inhalt der QuelleLocasciulli, A., M. Santamaria, G. Masera, E. Schiavon, A. Alberti und G. Realdi. „Hepatitis B virus markers in children with acute leukemia: The effect of chemotherapy“. Journal of Medical Virology 15, Nr. 1 (Januar 1985): 29–33. http://dx.doi.org/10.1002/jmv.1890150105.
Der volle Inhalt der QuelleYeo, Winnie, Paul K. S. Chan, Henry L. Y. Chan, Frankie K. F. Mo und Philip J. Johnson. „Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis“. Journal of Medical Virology 65, Nr. 3 (2001): 473–77. http://dx.doi.org/10.1002/jmv.2060.
Der volle Inhalt der QuelleDe Clercq, Erik. „Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections“. International Journal of Antimicrobial Agents 7, Nr. 3 (August 1996): 193–202. http://dx.doi.org/10.1016/s0924-8579(96)00319-6.
Der volle Inhalt der QuelleIshii, T., M. Hosoya, S. Mori, S. Shigeta und H. Suzuki. „Effective ribavirin concentration in hamster brains for antiviral chemotherapy for subacute sclerosing panencephalitis.“ Antimicrobial Agents and Chemotherapy 40, Nr. 1 (Januar 1996): 241–43. http://dx.doi.org/10.1128/aac.40.1.241.
Der volle Inhalt der QuelleCingarlini, Sara. „Unusual Presentations for EBV and HHV8 Co-Infections: A Case Report and Review of Literature“. Journal of Clinical Case Studies Reviews & Reports 5, Nr. 9 (30.09.2023): 1–6. http://dx.doi.org/10.47363/jccsr/2023(5)258.
Der volle Inhalt der QuelleZumla, A., und S. L. Croft. „Chemotherapy and immunity in opportunistic parasitic infections in AIDS“. Parasitology 105, S1 (Januar 1992): S93—S101. http://dx.doi.org/10.1017/s0031182000075405.
Der volle Inhalt der QuelleIlyushina, Natalia A., Erich Hoffmann, Rachelle Salomon, Robert G. Webster und Elena A. Govorkova. „Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice“. Antiviral Therapy 12, Nr. 3 (01.04.2006): 363–70. http://dx.doi.org/10.1177/135965350701200302.
Der volle Inhalt der QuelleSjöberg, Anita Herrström, Liya Wang und Staffan Eriksson. „Antiviral Guanosine Analogs as Substrates for Deoxyguanosine Kinase: Implications for Chemotherapy“. Antimicrobial Agents and Chemotherapy 45, Nr. 3 (01.03.2001): 739–42. http://dx.doi.org/10.1128/aac.45.3.739-742.2001.
Der volle Inhalt der QuelleYeo, Winnie, Paul K. S. Chan, Pun Hui, Wing M. Ho, Kwok C. Lam, Wing H. Kwan, Sheng Zhong und Philip J. Johnson. „Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study“. Journal of Medical Virology 70, Nr. 4 (02.06.2003): 553–61. http://dx.doi.org/10.1002/jmv.10430.
Der volle Inhalt der QuelleChen, Jungang, Samantha Kendrick und Zhiqiang Qin. „Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas“. Viruses 11, Nr. 12 (16.12.2019): 1161. http://dx.doi.org/10.3390/v11121161.
Der volle Inhalt der QuelleZon, Robin T., und Michael N. Neuss. „ASCO Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases“. Journal of Oncology Practice 6, Nr. 4 (Juli 2010): 193–94. http://dx.doi.org/10.1200/jop.777007.
Der volle Inhalt der QuelleUchiyama, Michihiro, Yotaro Tamai und Takashi Ikeda. „Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma“. International Journal of Infectious Diseases 14, Nr. 3 (März 2010): e265-e266. http://dx.doi.org/10.1016/j.ijid.2009.04.014.
Der volle Inhalt der QuelleKorzh, Elena V. „Interstitial lung diseases in persons infected with human immunodeficiency virus“. PULMONOLOGIYA 33, Nr. 6 (13.12.2023): 841–48. http://dx.doi.org/10.18093/0869-0189-2023-33-6-841-848.
Der volle Inhalt der QuelleGreiner, Timothy, James O. Armitage und Thomas G. Gross. „Atypical Lymphoproliferative Diseases“. Hematology 2000, Nr. 1 (01.01.2000): 133–46. http://dx.doi.org/10.1182/asheducation.v2000.1.133.133.
Der volle Inhalt der QuelleGreiner, Timothy, James O. Armitage und Thomas G. Gross. „Atypical Lymphoproliferative Diseases“. Hematology 2000, Nr. 1 (01.01.2000): 133–46. http://dx.doi.org/10.1182/asheducation.v2000.1.133.20000133.
Der volle Inhalt der QuelleKOTLYAR, V. K., S. V. FEDOROVICH und O. L. SEGET. „IMPROVEMENT OF GRAPE CUTTINGS BY THERMOTHERAPY AGAINST GLRAV-3 VIRUS“. Scientific Works of North Caucasian Federal Scientific Center of Horticulture Viticulture Wine-making 37 (September 2023): 107–10. http://dx.doi.org/10.30679/2587-9847-2023-37-107-110.
Der volle Inhalt der QuelleNowak, J. S., und D. Januszkiewicz. „CHEMOTHERAPY OF CHILDREN WITH LYMPHOPROLIFERATIVE DISEASES AS A RISK FACTOR FOR HEPATITIS C VIRUS INFECTION. 127“. Pediatric Research 41, Nr. 5 (Mai 1997): 770. http://dx.doi.org/10.1203/00006450-199705000-00146.
Der volle Inhalt der QuelleRamphal, Raveena, Ronald M. Grant, Biljana Dzolganovski, Julie Constantin, Raymond Tellier, Upton Allen, Sheila Weitzman, Anne Matlow, Martin Petric und Lillian Sung. „Herpes Simplex Virus in Febrile Neutropenic Children Undergoing Chemotherapy for Cancer“. Pediatric Infectious Disease Journal 26, Nr. 8 (August 2007): 700–704. http://dx.doi.org/10.1097/inf.0b013e31805cdc11.
Der volle Inhalt der QuelleNishida, Tsutomu, Naoki Hiramatsu, Masao Mizuki, Izumi Nagatomo, Hiroshi Kida, Keiko Tazumi, Shinichiro Shinzaki et al. „Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic“. Hepatology Research 43, Nr. 4 (06.08.2012): 339–46. http://dx.doi.org/10.1111/j.1872-034x.2012.01073.x.
Der volle Inhalt der QuelleShahgolzari, Mehdi, Srividhya Venkataraman, Anne Osano, Paul Achile Akpa und Kathleen Hefferon. „Plant Virus Nanoparticles Combat Cancer“. Vaccines 11, Nr. 8 (25.07.2023): 1278. http://dx.doi.org/10.3390/vaccines11081278.
Der volle Inhalt der QuellePolyakov, Yu Yu, E. A. Baryakh, E. N. Misyurina, E. I. Zhelnova, M. A. Mingalimov, S. A. Kardovskaya, M. Ya Smolyarchuk et al. „Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2“. Oncohematology 19, Nr. 2 (02.04.2024): 101–8. http://dx.doi.org/10.17650/1818-8346-2024-19-2-101-108.
Der volle Inhalt der QuelleIslas-Muñoz, B., B. Méndez-Sotelo, J. Reyes-Pérez, M. Jiménez-de los Santos, R. Herrera-Goepfert und P. Volkow-Fernández. „Obstructive cholangiopathy patient caused by cytomegalovirus and Kaposi sarcoma in a person living with HIV and hepatitis C“. International Journal of STD & AIDS 31, Nr. 11 (04.08.2020): 1110–13. http://dx.doi.org/10.1177/0956462420943027.
Der volle Inhalt der QuelleLi, Shu, Xiao-Yu Liu, Qiu Pan, Jian Wu, Zhi-Hao Liu, Yong Wang, Min Liu und Xiao-Lian Zhang. „Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells“. Viruses 11, Nr. 4 (24.04.2019): 378. http://dx.doi.org/10.3390/v11040378.
Der volle Inhalt der QuelleCastelli, Roberto, Riccardo Schiavon, Carlo Preti und Laurenzia Ferraris. „HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy“. Cardiovascular & Hematological Disorders-Drug Targets 20, Nr. 3 (26.11.2020): 175–80. http://dx.doi.org/10.2174/1871529x20666200415121009.
Der volle Inhalt der QuellePham, Hoang. „Mathematical Modeling the Time-Delay Interactions between Tumor Viruses and the Immune System with the Effects of Chemotherapy and Autoimmune Diseases“. Mathematics 10, Nr. 5 (27.02.2022): 756. http://dx.doi.org/10.3390/math10050756.
Der volle Inhalt der QuellePuig-Basagoiti, Francesc, Tia S. Deas, Ping Ren, Mark Tilgner, David M. Ferguson und Pei-Yong Shi. „High-Throughput Assays Using a Luciferase-Expressing Replicon, Virus-Like Particles, and Full-Length Virus for West Nile Virus Drug Discovery“. Antimicrobial Agents and Chemotherapy 49, Nr. 12 (Dezember 2005): 4980–88. http://dx.doi.org/10.1128/aac.49.12.4980-4988.2005.
Der volle Inhalt der QuelleBeck, Sungjun, Zhe Zhu, Michelli F. Oliveira, Davey M. Smith, Jeremy N. Rich, Jean A. Bernatchez und Jair L. Siqueira-Neto. „Mechanism of Action of Methotrexate Against Zika Virus“. Viruses 11, Nr. 4 (10.04.2019): 338. http://dx.doi.org/10.3390/v11040338.
Der volle Inhalt der QuelleLoginova, S. Ya, V. N. Schukina, S. V. Savenko, R. V. Sakharov und S. V. Borisevich. „Study of the Activity of Antiviral Drugs Against the Causative Agent of Chikungunya Fever in Cell Culture“. Antibiotics and Chemotherapy 67, Nr. 11-12 (11.02.2023): 10–15. http://dx.doi.org/10.37489/0235-2990-2022-67-11-12-10-15.
Der volle Inhalt der Quelle